About the Oncotype MAP Pan-Cancer Tissue Test
The management of advanced prostate cancer is evolving at a rapid pace, and Exact Sciences is here as your prostate cancer diagnostic partner.
Patients with advanced prostate cancer benefit from answers that provide clarity about appropriate therapy options and enable confident, timely treatment decisions. Patients who eventually progress on hormonal agents require reliable testing to determine eligibility for targeted therapeutic options. The Oncotype MAP Pan-Cancer Tissue Test can meet these demands by delivering comprehensive tumor profiling and identifying actionable genomic and proteomic alterations within 3-5 business days.*†
This test uses next-generation sequencing (NGS) and a broad array of tumor-specific and single immunohistochemical (IHC) stains to identify clinically relevant genomic alterations from patient specimens as small as 3 mm2 of tissue‡ with 15% tumor content
, about the size of a grain of rice.
Advantages of the test for Advanced Prostate Cancer
Informs eligibility for PARP Inhibitors and pembrolizumab as well as clinical trials
Provides NGS (next-generation sequencing) on 250+ genes and IHC (immunohistochemical) results on 20+ protein markers
Reliable results quickly delivered with minimal tissue requirements
Optimizing Treatment for Advanced Prostate Cancer Patients
recommend tumor testing in patients with metastatic prostate cancer to identify genomic alterations associated with targeted therapies. For example:
- Homologous recombination repair (HRR) pathway gene alterations, which are found in 25-30 percent of metastatic castration-resistant prostate cancer (mCRPC) tumors, indicate that the use of poly (ADP-ribose) polymerase (PARP) inhibitors, platinum chemotherapy, or clinical trial inclusion may be appropriate.
- Microsatellite instability-high (MSI-H) and mismatch repair deficiency (MMR-D) indicate that the use of pembrolizumab may be appropriate.
Oncotype MAP Pan-Cancer Tissue test reports are updated with new NCCN guideline recommendations and active clinical trials. This helps urologists stay up to date on the latest treatment options when determining crucial next steps for metastatic prostate cancer patients.
Why Choose the Oncotype MAP Pan-Cancer Tissue Test?
The Oncotype MAP Pan-Cancer Tissue Test can provide in-depth insights into alterations of hundreds of cancer-related genes, usually before the patient’s next follow-up visit.
- 257 Genes, 11 select fusions
- HHR gene mutations
- NGS and IHC results for PARP inhibitors and immunotherapy
- Continuously updated to include enrolling clinical trials
Gold standard tissue testing for enhanced sensitivity
- Acceptable samples as small as 3mm2 with ≥15% tissue content
- Leverages a proprietary method designed for smaller specimens enabling a lower failure rate
Results reported in 3-5 business days
- Designed to fit within existing workstreams
- QNS results in as few as 2 business days
Relevant Biomarkers for Advanced Prostate Cancer
*≥10 mutations per megabase
|Detected mutations and biomarkers
|HRR gene mutations
||Olaparib and Rucaparib
|ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, PALB2, RAD51C, RAD51D
||MSI / MMR-Deficiency
||MLH1, MSH2, MSH6, PMS2
The Oncotype MAP Pan-Cancer Tissue Test is most appropriate for patients with advanced, metastatic, refractory, relapsed or recurrent cancer. The test can also provide valuable data and analysis to inform treatment decisions where no standard of care exists.
How to Interpret the Results
The easy-to-interpret report includes NCCN®
/FDA actionable indications for therapy, as well as additional evidence-based therapies and clinical trials, based on the individual patient’s test results and key biomarkers.
Oncotype MAP Pan-Cancer Tissue test focuses on therapy selection for today and captures emerging markers that may find their way into guidelines tomorrow.